[1]张继续,吴 军,张 沅,等.肝细胞癌患者TACE治疗前后增强CT参数变化及与临床疗效关系[J].介入放射学杂志,2026,(01):38-45.[doi:10.3969/j.issn.1008-794X.2026.01.007 ]
　TACE ZHANG Jixu,WU Jun,ZHANG Yuan,et al.The correlation between the changes in contrast-enhanced CT parameters and clinical efficacy in patients with hepatocellular carcinoma after receiving[J].J Intervent Med,2026,(01):38-45.[doi:10.3969/j.issn.1008-794X.2026.01.007 ]
点击复制

肝细胞癌患者TACE治疗前后增强CT参数变化及与临床疗效关系()

PDF下载中关闭

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2026年01
页码:
38-45
栏目:
肿瘤介入
出版日期:
2026-01-25

文章信息/Info

Title:
The correlation between the changes in contrast-enhanced CT parameters and clinical efficacy in patients with hepatocellular carcinoma after receiving
文章编号:
1008-794X(2026)-001-0038-08
作者:
张继续;  吴 军;  张 沅;  杨祯忠;  许晓冬;  王 琳
730000 甘肃兰州 兰州市第二人民医院放射科(张继续、吴 军、张 沅、杨祯忠、许晓冬); 甘肃中医药大学附属第一医院放射科(王 琳)
Author(s):
TACE ZHANG Jixu; WU Jun; ZHANG Yuan; YANG Zhenzhong; XU Xiaodong; WANG Lin.
Department of Radiology,Lanzhou Municipal Second People's Hospital,Lanzhou,Gansu Province 730000,China
关键词:
肝细胞肝癌;  经动脉导管化疗栓塞术;  增强CT扫描;  临床疗效;  相关性
分类号:
R735.7
DOI:
10.3969/j.issn.1008-794X.2026.01.007
文献标志码:
A
摘要:
目的 探讨肝细胞癌(HCC)患者经动脉灌注化疗栓塞术(TACE)治疗前后增强CT(contrast-enhanced CT,CECT)参数变化及与临床疗效关系。方法 前瞻性选取2021年9月至2024年10月兰州市第二人民医院收治的106例HCC患者纳入研究,均予以TACE治疗及CECT扫描,比较患者治疗前、治疗后6个月CECT参数水平的差异,并据疗效评价标准将患者分为有效组及无效组,应用ROC曲线及曲线下面积(AUC)分析治疗前后CECT参数变化与疗效的关系。结果 随访6个月,与治疗前比较,106例HCC患者TACE治疗后CECT参数病灶强化达峰时间(TP)延长(P<0.05),强化峰值(PH)、病灶与主动脉强化峰值之比(M/A)、灌注值水平均降低(P<0.05)。TACE总有效率为67.92%(72/106),据此分为有效组(n=72)及无效组(n=34),两组治疗前后TP、M/A及△TP、△M/A水平比较差异无统计学意义(P>0.05); 与治疗前比较,治疗后PH、灌注值水平有效组均降低,无效组均升高(P<0.05),且有效组均低于无效组(P<0.05); 与无效组比较,有效组△PH、△灌注值水平均升高,Child-Pugh分级B级占比降低(P<0.05)。ROC曲线结果显示,CECT参数△PH、△灌注值单独及联合评估HCC患者TACE临床疗效的AUC分别为0.864、0.829、0.918(P<0.05),且以联合检测的灵敏度、特异度最高。多因素logistic回归分析结果显示,Child-Pugh分级B级、合并乏血供肿瘤是影响HCC患者TACE疗效的危险因素(P<0.05)。结论 HCC患者TACE治疗后CECT参数PH、灌注值、M/A下降,TP升高,其中PH、灌注值治疗前后的变化量可为TACE临床疗效的准确评估提供参考指导。

参考文献/References:

[1] Singal AG,Ng M,Kulkarni A.Advancing surveillance strategies for hepatocellular carcinoma:a new era of efficacy and precision[J].J Clin Exp Hepatol,2024,14:101448.
[2]杜 芳,王 娟,刘士岳,等.RDH16在肝细胞肝癌中的表达及预后分析[J].分子诊断与治疗杂志,2025,17:898-901,910.
Du F,Wang J,Liu SY,et al.The analysis of RDH16 expression and prognosis in hepatocellular carcinoma[J].J Mol Diagn Ther,2025,17:898-901,910.
[3]Zen Y.Intrahepatic cholangiocarcinoma:typical features,uncommon variants,and controversial related entities[J].Hum Pathol,2023,132:197-207.
[4]Yu HB,Hu JQ,Han BJ,et al.Combinatorial treatment with traditional medicinal preparations and VEGFR-tyrosine kinase inhibitors for middle-advanced primary liver cancer:a systematic review and meta-analysis[J].PLoS One,2024,19:e0313443.
[5]贾军梅,任江珊,张缭云.肝癌靶免治疗前肝损伤的现状及处理策略[J].中华肝脏病杂志,2023,31:1133-1136.
Jia JM,Ren JS,Zhang LY.Current status and treatment strategies for liver injury before targeted immunotherapy for liver cancer[J].Chin J Hepatol,2023,31:1133-1136.
[6]吴文清,谢聪颖,江龙委,等.肿瘤特异性个体化多靶点DC-CIK治疗原发性肝癌的临床疗效与安全性[J].中国肿瘤生物治疗杂志,2024,31:907-912.
Wu WQ,Xie CY,Jiang LW,et al.Clinical efficacy and safety of tumor-specific individualized multi-target DC-CIK therapy for primary liver cancer[J].Chin J Cancer Biother,2024,31:907-912.
[7]毕孝杨,邱瑞珍,杨福军,等.炎症预后指数联合双源CT灌注成像对肝癌TACE术后早期反应预测价值的临床研究[J].介入放射学杂志,2025,34:37-47.
Bi XY,Qiu RZ,Yang FJ,et al.Clinical value of inflammatory prognostic index combined with dual-source CT perfusion imaging in predicting early response of hepatocellular carcinoma after transcatheter hepatic artery chemoembolization[J].J Interv Radiol,2025,34:37-47.
[8]Kolligs F,Arnold D,Golfieri R,et al.Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma:Results from the prospective CIRT study[J].JHEP Rep,2023,5:100633.
[9]肝癌术后辅助治疗中国专家共识协作组,中国医师协会外科医师分会,中国抗癌协会肝癌专业委员会,等.肝癌术后辅助治疗中国专家共识(2023版)[J].中华消化外科杂志,2023:437-448.
Alliance of Chinese Expert Consensus on Postoperative Adjuvant Therapy for Hepatocellular Carcinoma,Chinese College of Surgeons,Committee of Liver Cancer,Chinese Anti-Cancer Association,et al.Chinese expert consensus on postoperative adjuvant therapy for hepatocellular carcinoma(2023 edition)[J].Chin J Dig Surg,2023:437-448.
[10]吴水天.CT增强扫描在评估原发性肝细胞肝癌TACE术后疗效中的应用[J].中国CT和MRI杂志,2022,20:91-93.
Wu ST.Application of contrast-enhanced CT scan in curative effect evaluation of primary hepatocellular carcinoma after TACE[J].Chin J CT MRI,2022,20:91-93.
[11]中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].临床肝胆病杂志,2020,36:277-292.
Bureau of Medical Administration,National Health Commission of the People's Republic of China.Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J].Chin J Clin Hepatol,2020,36:277-292.
[12]中国医师协会介入医师分会临床诊疗指南专委会.中国肝细胞癌经动脉化疗栓塞(TACE)治疗临床实践指南(2023年版)[J].中华医学杂志,2023,103:2674-2694.
Clinical Guidelines Committee of Chinese College of Interventionalists.Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma(2023 edition)[J].Natl Med J China,2023,103:2674-2694.
[13]Lencioni R,Llovet JM.Modified RECIST(mRECIST)assessment for hepatocellular carcinoma[J].Semin Liver Dis,2010,30:52-60.
[14]Singal AG,Kanwal F,Llovet JM.Global trends in hepatocellular carcinoma epidemiology:implications for screening,prevention and therapy[J].Nat Rev Clin Oncol,2023,20:864-884.
[15]Du JS,Hsu SH,Wang SN.The current and prospective adjuvant therapies for hepatocellular carcinoma[J].Cancers(Basel),2024,16:1422.
[16]Chen YW,Zhang JL,Hu WD,et al.Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma:a prospective,single-arm,phase Ⅱ study[J].Signal Transduct Target Ther,2024,9:280.
[17]韩 立,张 成,安东均,等.MRI-弥散加权成像技术及增强扫描在肝癌经导管动脉栓塞化疗术后疗效评估中的应用[J].癌症进展,2023,21:2074-2077.
Han L,Zhang C,An DJ,et al.Application of MRI-diffusion weighted imaging and enhancement scan in evaluating postoperative efficacy of transcatheter arterial chemoembo-lization for liver cancer[J].Oncol Prog,2023,21:2074-2077.
[18]龚 娜,朱冰洁,余佩君,等.CT动脉增强分数与肝癌TACE治疗效果的相关性研究[J].CT理论与应用研究,2023,32:67-73.
Gong N,Zhu BJ,Yu PJ,et al.Correlation between arterial enhancement fraction on CT and efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma[J].Comput Tomogr Theory Appl,2023,32:67-73.
[19]孙宏岗,孙达凯,王广平.计算机断层扫描对肝癌介入手术治疗效果和肿瘤活性及预后的评价[J].中国肿瘤临床与康复,2022,29:291-294.
Sun HG,Sun DK,Wang GP.Efficacy of CT scan in evaluation of postoperative efficacy,tumor activity and prognosis in patients undergoing interventional procedure for liver cancer[J].Chin J Clin Oncol Rehabil,2022,29:291-294.
[20]朱继兰,赵 霞,王市伟,等.多参数磁共振成像联合CT动态增强对晚期肝细胞癌免疫治疗疗效的预测价值[J].肝脏,2024,29:1040-1046.
Zhu JL,Zhao X,Wang SW,et al.The predictive value of multiparametric magnetic resonance imaging combined with CT dynamic enhancement on the efficacy of immunotherapy for patients with advanced hepatocellular carcinoma[J].Chin Hepatol,2024,29:1040-1046.
[21]Hu WC,Cao GH,Ye SL,et al.Quantitative analysis with multiphase contrast-enhanced computed tomography to evaluate residual tumor activity of hepatocellular carcinoma after DEB-TACE[J].Medicine(Baltimore),2023,102:e34054.
[22]刘儒鹏,陈美玲.CTPI灌注参数联合增强CT在原发性肝癌患者TACE术后评估中的应用[J].中国医学工程,2022,30:94-97.
Liu RP,Chen ML.Application of CTPI perfusion parameters combined with enhanced CT in evaluation of patients with primary liver cancer after TACE[J].China Med Eng,2022,30:94-97.
[23]冯坤鹏,王兴龙,董 备,等.肝癌TACE前后癌灶及癌旁CT灌注成像血流定量变化及指导疗效评估的价值[J].中国CT和MRI杂志,2024,22:102-105.
Feng KP,Wang XL,Dong B,et al.Quantitative changes of blood flow in focal and Para-cancerous CT perfusion imaging in liver cancer before and after tace and evaluation value in curative effect[J].Chin J CT MRI,2024,22:102-105.
(收稿日期:2025-06-09)
(本文编辑:元 禾)

相似文献/References:

[1]袁正,叶晓丹,董生,等.３１ P－MR波谱分析技术评价化疗栓塞治疗肝细胞癌疗效的初步研究[J].介入放射学杂志,2008,(11):779.
　YUAN Zheng,YE Xiaodan,DONG Sheng,et al.Value of ３１ P MR spectroscopy in monitoring the early response of hepatocellular carcinoma to transcatheter arterial chemoembolization[J].J Intervent Med,2008,(01):779.
[2]郭建海,杨仁杰.血清nm２３－H１水平对肝细胞肝癌TACE治疗预后的影响[J].介入放射学杂志,2010,(06):463.
　GUO Jianhai,Yang Renjie.Impact of serum nm２３－H１level on the prognosis of hepatocellular carcinoma after transcatheter arterial chemoembolization treatment[J].J Intervent Med,2010,(01):463.
[3]瞿旭东,王建华,颜志平,等.介入导入三氧化二砷微球对 VX２ 兔肝肿瘤模型的治疗作用[J].介入放射学杂志,2007,(03):184.
　QU Xu-dong,WANG Jian-hua,YAN Zhi-ping,et al.The treatment effect of As ２ O ３ -PLGA microspheres on VX２rabbits liver tumor models[J].J Intervent Med,2007,(01):184.
[4]张 雯,颜志平,罗剑钧,等.成功抢救下腔静脉癌栓支架植入后肺栓塞一例[J].介入放射学杂志,2011,(02):167.
　ZHANG Wen,YAN Zhi-ping,LUO Jian-jun,et al.Successful rescue of pulmonary embolism in HCC patient after stent implantation[J].J Intervent Med,2011,(01):167.
[5]罗剑钧,颜志平,王建华,等.植入 125 I籽源条及金属支架联合经动脉化疗栓塞治疗肝癌合并下腔静脉梗阻的初步经验[J].介入放射学杂志,2009,(11):827.
　LUO Jianjun,YAN Zhiping,WANG Jianhua,et al.Implantation of radioactive １２５ I seed strand and metallic stent combined with TACE for the treatment of HCC with IVC obstruction：initial results in８patients[J].J Intervent Med,2009,(01):827.
[6]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].J Intervent Med,2012,(01):636.
[7]陈晓明,张 靖,祖茂衡.加强肝癌根治性介入治疗的理念与临床研究[J].介入放射学杂志,2025,34(08):805.[doi:10.3969/j.issn.1008-794X.2025.08.001 ]
　CHEN Xiaoming,ZHANG Jing,ZU Maoheng..Strengthening the concept and clinical research of radical interventional therapy for liver cancer[J].J Intervent Med,2025,34(01):805.[doi:10.3969/j.issn.1008-794X.2025.08.001 ]

备注/Memo

备注/Memo:
通信作者: 王 琳 E-mail:zhangjxdr@163.com
更新日期/Last Update: 2026-01-25